Pharmakopsychiatrie, Neuro-Psychopharmakologie最新文献

[Effect of high single doses of bromocriptine in schizophrenic patients with elevated serum prolactin levels and extrapyramidal side effects associated with neuroleptic treatment (author's transl)]. [高单次剂量溴隐亭对抗精神病药治疗伴有血清催乳素水平升高和锥体外系副作用的精神分裂症患者的影响[作者译]。

Pharmakopsychiatrie, Neuro-Psychopharmakologie Pub Date : 1980-11-01 DOI: 10.1055/s-2007-1019649

E Ringwald, A Lustig, M Moscovici, R Spiegel, E Vamos

{"title":"[Effect of high single doses of bromocriptine in schizophrenic patients with elevated serum prolactin levels and extrapyramidal side effects associated with neuroleptic treatment (author's transl)].","authors":"E Ringwald, A Lustig, M Moscovici, R Spiegel, E Vamos","doi":"10.1055/s-2007-1019649","DOIUrl":"https://doi.org/10.1055/s-2007-1019649","url":null,"abstract":"The purpose of the present study was to investigate the effect of bromocriptine in single doses of 20 and 30 mg on the unwanted effects most frequently caused by neuroleptics: elevated prolactin levels and extrapyramidal disturbances. 111 chronic schizophrenics were included in the investigations, 58 of them being treated with haloperidol and 53 with chlorpromazine. It was found that a single dose of 30 mg bromocriptine brought about a statistically significant decrease in the prolactin levels of patients treated with haloperidol but produced no more than a downward tendency in patients receiving chlorpromazine (the initial prolactin levels of both groups of patients were equal.) The effect of bromocriptine on EPS disturbances was more marked in the chlorpromazine group, but side effects such as nausea and agitation also occurred more frequently in this group. These results show that there is no correlation between the reduction in prolactin levels produced by bromocriptine and an improvement in unwanted EPS effects. This supports the hypothesis that the effect of neuroleptics on the prolactin secreting cells of the anterior pituitary and their effect on the EPS are mediated by different sets of receptors.","PeriodicalId":76325,"journal":{"name":"Pharmakopsychiatrie, Neuro-Psychopharmakologie","volume":"13 6","pages":"318-24"},"PeriodicalIF":0.0,"publicationDate":"1980-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1055/s-2007-1019649","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17177636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Guidelines for the clinical evaluation of analgesic drugs. 镇痛药物临床评价指南。

Pharmakopsychiatrie, Neuro-Psychopharmakologie Pub Date : 1980-11-01

引用次数: 0

Effect of L-tryptophan on apomorphine-induced growth hormone secretion in normal subjects. l -色氨酸对正常受试者阿吗啡诱导的生长激素分泌的影响。

Pharmakopsychiatrie, Neuro-Psychopharmakologie Pub Date : 1980-11-01 DOI: 10.1055/s-2007-1019651

S Lal, S N Young, P Cervantes, H Guyda

引用次数: 5

[Paradoxical akinesia induced by antidepressant drugs (author's transl)]. [抗抑郁药物引起的矛盾运动障碍(作者译)]。

Pharmakopsychiatrie, Neuro-Psychopharmakologie Pub Date : 1980-11-01 DOI: 10.1055/s-2007-1019652

J Böning

引用次数: 1

Basal and stimulated levels of prolactin, TSH and LH in serum of chronic schizophrenic patients, long-term treated with neuroleptics. 长期服用抗精神病药的慢性精神分裂症患者血清泌乳素、促甲状腺激素和LH的基础和刺激水平。

Pharmakopsychiatrie, Neuro-Psychopharmakologie Pub Date : 1980-11-01 DOI: 10.1055/s-2007-1019650

D Naber, M Ackenheil, G Laakman, H Fischer, K von Werder

引用次数: 25

[Psychotropic drugs and pregnancy: a review (author's transl)]. 精神药物与妊娠:综述[作者简介]。

Pharmakopsychiatrie, Neuro-Psychopharmakologie Pub Date : 1980-11-01 DOI: 10.1055/s-2007-1019648

C Thiels

引用次数: 4

Anxiety and its treatment. Symposium of the Section Committee on Pharmacopsychiatry of the World Psychiatric Association, St. Moritz, 1979. 焦虑及其治疗。世界精神病学协会药物精神病学分会委员会专题讨论会，圣莫里茨，1979年。

Pharmakopsychiatrie, Neuro-Psychopharmakologie Pub Date : 1980-09-01

引用次数: 0

Des-tyrosyl-gamma-endorphin in schizophrenia: a double-blind trial in 13 patients. 去-酪氨酸- γ -内啡肽在精神分裂症中的作用:13例患者的双盲试验。

Pharmakopsychiatrie, Neuro-Psychopharmakologie Pub Date : 1980-09-01 DOI: 10.1055/s-2007-1019647

H M Emrich, M Zaudig, W Kissling, G Dirlich, D von Zerssen, A Herz

{"title":"Des-tyrosyl-gamma-endorphin in schizophrenia: a double-blind trial in 13 patients.","authors":"H M Emrich, M Zaudig, W Kissling, G Dirlich, D von Zerssen, A Herz","doi":"10.1055/s-2007-1019647","DOIUrl":"https://doi.org/10.1055/s-2007-1019647","url":null,"abstract":"A double-blind placebo-controlled cross-over investigation of the possible antipsychotic action of [des-Tyr1]-gamma-endorphin (DT gamma E) was undertaken in schizophrenic patients. This non-opiod derivative of gamma-endorphin has recently been shown to exert both neuroleptic-like effects in animals and an antipsychotic action in schizophrenic patients failing to respond to conventional neuroleptic therapy. 13 patients undergoing continuous neuroleptic therapy, and suffering from either chronic or acute, frequently-relapsing schizophrenia and displaying persistent productive symptoms (hallucinations, acute delusions) were selected for the trial. After one day of single-blind injection of placebo, two successive double-blind treatment periods of 4 days each followed, viz 4 days with i.m. injections of 2 mg DT gamma E preceding 4 days of placebo injections or vice versa. Psychopathological evaluation was performed twice daily by use of the IMPS and an eight-point-scale appropriate for the estimation of special target symptoms (VBS). The mean data obtained from the whole sample of 13 patients show that placebo and DT gamma E produce a reduction in symptomatology of an appoximately equal magnitude. The results provide no support for the hypothesis of an antipsychotic efficacy of DT gamma E in the treatment of chronic schizophrenic patients. In the subgroup of acute cases, however, a therapeutic action of DT gamma E appears possible","PeriodicalId":76325,"journal":{"name":"Pharmakopsychiatrie, Neuro-Psychopharmakologie","volume":"13 5","pages":"290-8"},"PeriodicalIF":0.0,"publicationDate":"1980-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1055/s-2007-1019647","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18052263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 28

Psychiatric uses of beta-blockers. -受体阻滞剂的精神病学应用。

Pharmakopsychiatrie, Neuro-Psychopharmakologie Pub Date : 1980-09-01 DOI: 10.1055/s-2007-1019644

H Cuche, P Deniker

引用次数: 8

Psychopharmacology and psychotherapy in the treatment of anxiety. 精神药理学与心理疗法治疗焦虑。

Pharmakopsychiatrie, Neuro-Psychopharmakologie Pub Date : 1980-09-01 DOI: 10.1055/s-2007-1019646

A M Freedman

{"title":"Psychopharmacology and psychotherapy in the treatment of anxiety.","authors":"A M Freedman","doi":"10.1055/s-2007-1019646","DOIUrl":"https://doi.org/10.1055/s-2007-1019646","url":null,"abstract":"The symptom of anxiety, perhaps the most common in all clinical medicine, presents in a variety of forms--psychologic, somatic, behavioral--and often masquerades or is misdiagnosed. Anxiety is a manifestation encountered in a heterogeneous group of syndromes or disorders embracing all of psychiatry. It is necessary to develop the best treatment or combination of treatments appropriate for each case or group of cases. In the treatment of anxiety controlled comparative studies indicate that patients receiving psychotherapy do better than controlled groups. According to present knowledge no one method of psychotherapy is superior to others. The effectiveness of pharmacotherapy alone in the treatment of anxiety is unequivocally established. However, combined therapy of pharmacologic agents and psychotherapy would appear to be superior to either therapy alone. Critical research using existing modalities and combinations of modalities is of vital importance in the treatment of anxiety. Rapid developments in the past twenty-five years in the discovery and differential use of pharmacotherapeutic agents have stimulated renewed interest in the anxiety states and related disorders, as has the emerging body of knowledge regarding possible specific receptor sites in the brain related to anxiety. These developments have heightened interest in research on anxiety with resulting innovations in treatment.","PeriodicalId":76325,"journal":{"name":"Pharmakopsychiatrie, Neuro-Psychopharmakologie","volume":"13 5","pages":"277-89"},"PeriodicalIF":0.0,"publicationDate":"1980-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1055/s-2007-1019646","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18454893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 15